Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Entrada Therapeutics, Inc. (TRDA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
33.83-1.17 (-3.34%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close35.00
Open35.00
Bid33.00 x 1100
Ask33.78 x 800
Day's Range33.43 - 36.85
52 Week Range20.00 - 36.85
Volume277,158
Avg. Volume268,750
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Entrada Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

    BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular therapeutics company by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat during the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, Decem

  • Benzinga

    4 Stocks Insiders Are Buying

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Entrada Therapeutics The

  • GlobeNewswire

    Entrada Therapeutics Announces Closing of Initial Public Offering

    BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines and aiming to become the world’s foremost intracellular therapeutics company, today announced the closing of its initial public offering of 9,075,000 shares of common stock, at a price to the public of $20.00 per share. All shares were offered by Entrada. The

Advertisement
Advertisement